SML3914

Cabozantinib

≥98% (HPLC)

• 别名: BMS 907351, BMS-907351, BMS907351, N-(4-(6,7-Dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane1,1-dicarboxamide, N-(4-{[6,7-bis(Methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, XL 184, XL-184, XL184
• 经验公式（希尔记法）: C₂₈H₂₄FN₃O₅
• CAS号: 849217-68-1
• 分子量: 501.51
• MDL號碼: MFCD20926324
• 分類程式碼代碼: 12352200
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: -10 to -25°C

说明

生化／生理作用

Cabozantinib (XL184; BMS‐907351) is an orally active, potent inhibitor against multiple receptor tyrosine kinases, notably VEGFR2/KDR (IC50 = 35 pM), MET (IC50 = 1.3 nM/wt, 3.8 nM/Y1248H, 11.8 nM/D1246N, 14.6 nM/K1262R), KIT, RET, AXL, TIE2, and FLT3 (IC50 = 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib inhibits MET-driven proliferation in cancer cultures (IC50 = 9.9 nM/Hs746T, 19 nM/SNU-5) and simultaneously suppressing metastasis, angiogenesis and tumor growth in vivo (3-100 mg/kg via single or daily p.o. to mice with human MDA-MB-231 xenograft, 1-60 mg/kg via single or daily p.o. to rats with C6 rat glioma).

安全信息

• 象形圖: GHS08,GHS07
• 訊號詞: Danger
• 危險聲明: H302,H360FD,H373
• 防範說明: P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313
• 危險分類: Acute Tox. 4 Oral - Repr. 1B - STOT RE 2
• 標靶器官: Bone marrow,Kidney,Endocrine system,Gastrointestinal tract,Liver
• 儲存類別代碼: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable